Cyclopentolate

When ATH:
S01FA04

Characteristic.

Molecular weight 327,85. Solutions for ophthalmic use are borate buffered solutions cyclopentolate hydrochloride.

Pharmacological action.
Holinoliticheskoe, midriaticheskoe.

Application.

Ophthalmology Diagnostics (funduscopy, refractometry and others.), to create mydriasis in inflammatory diseases of the anterior eye (episcleritis, scleritis, keratit, iridocyclitis, uveitis) and during the preoperative cataract extraction with.

Contraindications.

Hypersensitivity, zakrыtougolynaya glaucoma, predisposition for violation of the outflow of intraocular fluid (narrow or closed angle of the eye).

Restrictions apply.

Age to 3 Months.

Pregnancy and breast-feeding.

Not recommended (may be subject to systemic absorption, insufficient experience in the clinical use).

Side effects.

From the nervous system and sensory organs: local — increasing intraocular pressure, photophobia, blurring of vision, burning, eye irritation, hyperemia, conjunctivitis, blefarokonъyunktyvyt, punctate keratitis, sinexii; dizziness, psychotic reactions, misconduct, ataxia, unusual sleepiness, weakness, incoherence, anxiety, hallucinations, superactivity, seizures, violation of the temporal and spatial orientation.

Other: skin rashes, bloating in children, thirst or dry mouth, nausea, tachycardia, hyperpyrexia, vasodilation, urinary retention, weakening of gastrointestinal motility, reduced secretion glands (sweat, Salivary, mucous membranes of upper respiratory tract and bronchi).

Cooperation.

The effect of cyclopentolate may enhance alpha-adrenoceptor agonists (Phenylephrine), weaken-m-holinomimetiki (pilocarpine). Cyclopentolate antiglaucoma and reduces the effects of carbachol myotic, pilocarpine and anticholinesterase agents.

Overdose.

Treatment: in severe cases, administered (in / slow, may-n/a) antidote-fizostigmina salicylate; adults and teenagers — 2 mg, When you save the signs of intoxication is 1-2 mg 20 m; Children - 0,5 mg (when persistent toxic effects, and the absence of cholinergic symptoms may re-introduction through 5 m up to a maximum cumulative dose is 2 mg).

Dosing and Administration.

Locally, digging into the conjunctival sac. In inflammatory diseases of the eye - By 1 drop 3 once a day, in severe cases, every 3-4 h. For mydriasis - 1-2 drops 1-3 times with an interval of 10-20 min.

Precautions.

Children up 2 years is not recommended for use in concentrations above 0,5 %. To use caution in the elderly and patients, with the risk of increased intraocular pressure, Down's syndrome, in children with spastic paralysis or brain damage, in fair-skinned, blue-eyed children (characterized by a heightened sensitivity to the action of cyclopentolate).

Less effective in people with dark pigmented irises (Residual accommodation can reach 2,0-4,0 D).

In children, the presence of semiproof or persistent spasm of accommodation is best used for cycloplegic instillation of atropine Course.

Patients older 40 s use of cyclopentolate requires control of intraocular pressure and (if necessary) of gonioscopy.

Cautions.

To reduce systemic absorption recommended pressed nasolacrimal point during the procedure and for 2-3 min thereafter (especially in children). Babies, in connection with a possible food intolerance, feeding is recommended to be performed no earlier than 4 hours after treatment. In the event of photophobia to protect the eyes from UV light is necessary to wear sunglasses. If fotofobia and/or dimming of vision does not go away within 36 h after instillation, Talk to your doctor.

Patients with hypersensitivity to atropine do not give cross-allergy to cyclopentolate.

Cooperation